Essential thrombocythaemia in children: is a treatment needed?

Bibliography

• RANDI ML, FABRIS F, GIROLAMI A:Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leak. Lymph. (1997) 37:379–385.
   Google Scholar
• MURPHY S: Thrombocytosis and thrombocythemia. Clin. Haematul (1983) 12:89–106.
   PubMedGoogle Scholar
• MICHIELS JJ, VAN GENDEREN PJJ: Essential thrombocythemia in childhood. Semin. Thrumb. Hemost. (1997) 23:295–301.
   PubMed Web of Science ®Google Scholar
• SUTOR AH: Thrombocytosis in childhood. Semin. Thrumb. Hemost. (1997) 21:330–339.
   Web of Science ®Google Scholar
• RANDI ML, STOCCO F, ROSSI C, TISON T, GIROLAMI A: Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). J. Med. (1991) 22:213–223.
   PubMedGoogle Scholar
• HARRISON CN, GALE RE, MACHIN SJ, LINCH DC: A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. iBlood i (1999) 93:417–424.
   PubMed Web of Science ®Google Scholar
• DROR Y, ZIPURSKY A, BLANCHETTE VS: Essential thrombocythemia in children. iPed. Hematul Oncul i (1999) 21:356–363.
   PubMed Web of Science ®Google Scholar
• •An extensive evaluation of ET in children.
   Google Scholar
• RANDI ML, PUTTI MC, FABRIS F, SAINATI L, ZANESCO L, GIROLAMI A: Features of essential thrombocythemia in childhood: a study of five children. iBr. J. Haematul i (2000) 108:86–89.
   PubMed Web of Science ®Google Scholar
• RIDELL B, CARNESKOG J, WEDEL H iet al.: i Incidence of chronic myeloproliferative disorders in the city of Goteborg, Sweeden 1983–1992. iEur: Hematul i (2000) 65:267–271.
   Google Scholar
• MESA RA, SILVERSTEIN MN, JACOBSEN SJ, WOLLAN PC, TEFFERI A: Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study 1976-1995. iAm.! Hematul i (1999) 61:10–15.
   PubMed Web of Science ®Google Scholar
• JENSEN MK, DENULLY BROWN P, NIELSEN 0J, HASSELBACH HC: Incidence, clinical features and outcome of essential thrombocythemia in a well defined geographical area. iEur: Haematul i (2000) 65:132–139.
   PubMed Web of Science ®Google Scholar
• GUGLIOTTA L, for the ITALIAN GROUP OF MYELOPROLIFERATIVE DISORDERS: Essential thrombocythemia: prognostic factors in the Italian series of two thousand patients. iHaematologica i (1999) 84\(Suppl. 9):9.
   Google Scholar
• ROZMAN C, GIRALT M, FELIU E, RUBIO D, CORTES MT: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. iCancer i (1991) 67:2658–2663.
   Google Scholar
• TEFFERI A, MURPHY S: Current opinion in essential thrombocythemia: pathogenesis diagnosis and management. iBlood Rev i (2001) 15:121–131.
   PubMed Web of Science ®Google Scholar
• BARBUI T: Indications for lowering platelet numbers in essential thrombocythemia. iSemin. Hematul i (2003) 40:22–25.
   Google Scholar
• •A comprehensive evaluation of cytoreductive drugs for ET.
   Google Scholar
• CORTELLAZZO S, VIERO P, FINAZZI G, D' EMILIO A, RODEGHIERO F, BARBUI T: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. iClin. Oncul i (1990) 8:556–562.
   PubMed Web of Science ®Google Scholar
• FINAZZI G, RUGGIERI M, RODEGHIERO F, BARBUI T: Second malignancies in patients with essential thrombocythemia treated with busulfan and hydroxyurea: long-term follow-up of a randomized clinical trial. iBr: J. Haematul i (2000) 110:577–583.
   PubMed Web of Science ®Google Scholar
• MURPHY S: Therapeutic dilemmas: balancing the risk of bleeding, thrombosis and leukemic transformation in myeloproliferative disorders (MPD). iThrumb. Hemostas. i (1997) 78:622–626.
   PubMed Web of Science ®Google Scholar
• HASLE H: Incidence of essential thrombocythemia in children. iBr: J. Haematul i (2000) 110: 751.
   PubMed Web of Science ®Google Scholar
• WIESTNER A, SCHLEMPER RJ, VAN DER MAAS AP: An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia. iNature genetics i (1998) 18:49–52.
   PubMed Web of Science ®Google Scholar
• YABRO JW: Mechanism of action of hydroxyurea. iSemin. Oncal i (1992) 19:1–10.
   Google Scholar
• NAND S, STOCK W, GODWIN J, FISHER SG: Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrmobocythemia and myeloid metaplasia with myelofibrosis. iAm. J. Hematul i (1996) 52:42–46.
   PubMed Web of Science ®Google Scholar
• FINAZZI G, RUGGERI M, RODEGHIERO F, BARBUI T: Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. iBlood (2003) i 101:3749.
   Google Scholar
• STERKERS Y, PREUDHOMME C, LAJ JL iet al.: i Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea : high proportion of cases with 17p deletion. iBlood i (1998) 91:616–622.
   Google Scholar
• KINNEY TR, HELMS RW, O'BRANSKI EE iet al.: i Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a Phase I/II trial. Pediatric Hydroxyurea Group. iBlood (1999) i 94:1550–1554.
   Google Scholar
• PASSAMONTI F,MALABARBA L, ORLANDI E iet al.: i Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. iHaematalogica i (2003) 88:13–18.
   Google Scholar
• KILADJIAN JJ, GARDIN C, RENOUX M, BRUNO F, BERNARD JF: Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. iHematul J. i (2003) 4(3):198–207.
   Google Scholar
• ALVARADO Y, CORTES J, VERSTOVSEK S iet al.: i Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. iCancer Chemiuter: Pharmacy] i (2003) 51:81–86.
   Google Scholar
• HERMANN J, FUCHS D, SAUERBREY A, HEMPLE L, ZINTL F: Successful treatment of essential thrombocythemia with anagrelide in a child. iMed. Pediatc Oncal i (1998) 30:367–371.
   PubMedGoogle Scholar
• SILVERSTEIN MN, PETITT RIVI, SOLBERG LAJ, FLEMING JS, KNIGHT RC, SCHACTER LP: Anagrelide: a new drug for treating thrombocytosis. iN Engl. J. Med. i (1988) 318:1292–1294.
   PubMed Web of Science ®Google Scholar
• STOREN E, TEFFERI A: Long-term use ofanagrelide in young patients with essential thrombocythemia. iB/ood(2001) i 97:863–866.
   Google Scholar
• •A critical evaluation of anagrelide in the young.
   Google Scholar
• CHINTAGUMPALA MM, STEUBER CP, MAHONEY DH, OGDEN AK, FERNBACH DJ: Essential thrombocythemia in a child: management with anagrelide. iAm. J. Pediatr. Hematol.Oncol. i (1991) 13:52–56.
   PubMedGoogle Scholar
• RANDI ML, ROSSI C, FARBIS F, MENAPACE L, GIROLAMI A: Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. iClin. Appl. Thromb. Hemost. i (1999) 5:131–135.
   PubMed Web of Science ®Google Scholar
• VAN GENDEREN PJJ, MICHIELS JJ, LINDEMANS J, VAN STRIK R, VAN VLIET HHDM: Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. iThrom. Haemost. i (1995) 73:210–214.
   PubMed Web of Science ®Google Scholar
• VAN GENDEREN PJJ, BUDDE U, MICHIELS JJ,VAN STRIK R, VAN VLIET HHDM: The reduction of large von Willebrand factor multimeres in plasma in essential thrombocythemia is related to the platelet count. iBr: J. Haematol. i (1996) 93:962–965.
   PubMedGoogle Scholar
• GRIESSHAMMER M, LANGER C: Pharmacotherapy of essential thrombocythemia: economic consideration. iExpert Opin Pharmacother. i (2003) 4:1499–1505.
   PubMed Web of Science ®Google Scholar
• •A report on economic issue regarding the treatment of ET.
   Google Scholar
• CORTELLAZZO S, FINAZZI G, RUGGERI M iet al.: i Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. iN Engl. Med. i (1995) 332:1132–1136.
   Google Scholar
• MCINTYRE KJ, HOAGLAND HC, SILVERSTEIN MN, PETITT PM: Essential thrombocythemia in young adults. iMayo Clin. Proc. i (1991) 66:149–154.
   PubMed Web of Science ®Google Scholar
• OZER SFL, WAYNE El, MIESCH DC,LEVIN WC: Primary hemorrhagic thrombocythemia. Am. iJ. Med. i (1960) 28:807–823.
   PubMed Web of Science ®Google Scholar
• SPACH MS, HOWELL DA, HARRIS JS: Myocardial infarction and multiple thrombosis ma child with primary thrombocytosis. iPediatrics i (1963) 31:268–276.
   PubMed Web of Science ®Google Scholar
• LUMLEY S: Essential thrombocythemiain childhood. iProc. Royal Soc. Med. i (1971) 64:6–7.
   PubMedGoogle Scholar
• FREEDMAN MH, OLICARIS RS, MCCLURE PD, WEINSTEIN L: Primary thrombocythemia in a child. iPediatr. i (1973) 83:163–164.
   Google Scholar
• SCEATS DJ, BAITLON D: Primary thrombocythemia in a child. iClin. Pediatr. i (1980) 19:298–300.
   Google Scholar
• BARNHART MI, KIM TH, EVATT BL iet al.: i Essential thrombocythemia in a child: platelet ultrastructure and function. iAm. J. Hematol. i (1981) 8:87–107.
   Google Scholar
• LINCH DC, HUTTON R, COWAN D, MOORE AR, RICHARDS JDM, WILKINSON LS: Primary thrombocythemia in childhood. iScand. Haematol. i (1982) 28:72–76.
   PubMedGoogle Scholar
• MITUS AJ, BARBUI T, SHULMAN LN iet al.: i Hemostatic complications in young patients with essential thrombocythemia. iAm. .1. Med. i (1990) 88:371–375 .
   Google Scholar
• KAPOOR G, CORREA H, YU LC: Essential thrombocythemia in an infant. iPed Hen-tato]. Oncol. i (1996) 18:381–383.
   PubMed Web of Science ®Google Scholar
• YOSHIDA N, ISHII E, KOGA N, KAMIMURA T, MIYAZAKI S: Analysis of thrombopoietin and c-mpl expression a child with essential thrombocythemia. iPed. Hematol. Oncol. i (1998) 15:359–363.
   PubMed Web of Science ®Google Scholar
• YANG RC, QIAN LS: Essential thrombocythemia in children: a report of nine cases. iBr. J. Haematol. i (2000) 110:1002–1014.
   Web of Science ®Google Scholar
• CHAN GCF, MA SK, HA SY, CHAN LC, LAU YL: Childhood essential thrombocythemia without evidence of myeloproliferation: how many investigations should be done? iBr. J. Haematol. i (2000) 110:1002–1014.
   Web of Science ®Google Scholar
• OKADA H, IMAI T, ITOH S, ISOBE K,ONISHI S: XYY male with essential thrombocythemia in childhood. iJ. Hematol. i (2000) 71:55-58. Affiliation Maria Luigia Randi MDT1,2 & Maria Caterina Putti MD3 TAuthor for correspondence
   Google Scholar